Drugs / OCTA-C1-INH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06361537 | Apr 2024 → Dec 2026 expected | hereditary angioedema | Octapharma | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCTA-C1-INH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361537 ↗ |
| Modality | Protein / enzyme biologic | “highly purified concentrate of human C1-INH prepared from pooled human plasma” NCT06361537 ↗ |
| Route | Intravenous | “the solution can be administered as a slow IV injection” NCT06361537 ↗ |